Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017

Details for Mechanism ID: 9171
Country/Region: Kenya
Year: 2016
Main Partner: Henry M. Jackson Foundation for the Advancement of Military Medicine
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USDOD
Total Funding: $12,125,987 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,704,195
Care: Orphans and Vulnerable Children (HKID) $721,464
Care: TB/HIV (HVTB) $398,848
Care: Pediatric Care and Support (PDCS) $350,170
Laboratory Infrastructure (HLAB) $1,450,098
Strategic Information (HVSI) $450,390
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $1,023,048
Prevention: HIV Testing and Counseling (HVCT) $1,783,725
Sexual Prevention: Other Sexual Prevention (HVOP) $197,826
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $1,041
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,130,944
Treatment: Adult Treatment (HTXS) $2,747,313
Treatment: Pediatric Treatment (PDTX) $166,925
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTC_TST_DSD Age/sex: <1 2017 6
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 199,353
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 199,625
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 40,346
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 40,483
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 479,508
HTC_TST_DSD Service Delivery Point (Community): Homebased testing 2017 17,076
HTC_TST_DSD Service Delivery Point (Community): Index testing 2017 7,800
HTC_TST_DSD Service Delivery Point (Community): Mobile testing 2017 9,275
HTC_TST_DSD Service Delivery Point (Facility): Index testing 2017 13,120
HTC_TST_DSD Service Delivery Point (Facility): Inpatient 2017 19,998
HTC_TST_DSD Service Delivery Point (Facility): Malnutrition facilities 2017 411
HTC_TST_DSD Service Delivery Point (Facility): Outpatient 2017 187,005
HTC_TST_DSD Service Delivery Point (Facility): Pediatric 2017 9,661
HTC_TST_DSD Service Delivery Point (Facility): PMTCT 2017 103,001
HTC_TST_DSD Service Delivery Point (Facility): TB Clinics 2017 2,631
HTC_TST_DSD Service Delivery Point (Facility): VCT 2017 96,898
HTC_TST_DSD Service Delivery Point (Facility): VMMC 2017 14,818
HTC_TST_DSD Sum of Aggregated Age/Sex 15+ 2017 398,978
HTC_TST_DSD Sum of Aggregated Age/Sex <15 2017 80,829
HTC_TST_DSD Sum of Aggregated Age/Sex disaggregates 2017 479,807
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 3,960
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 4,089
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Female 2017 1,720
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Male 2017 1,773
KP_PREV_DSD By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) 2017 5,220
KP_PREV_DSD By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 3,337
KP_PREV_DSD By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area 2017 510
KP_PREV_DSD By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 208
KP_PREV_DSD Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 3,545
KP_PREV_DSD Total estimated number of key population in the catchment area 2017 5,730
OVC_SERV_DSD Age/Sex: 18+ Female 2017 3,597
OVC_SERV_DSD Age/Sex: 18+ Male 2017 2,940
OVC_SERV_DSD By Aggregated Age/Sex: <18 Female 2017 6,889
OVC_SERV_DSD By Aggregated Age/Sex: <18 Male 2017 7,112
OVC_SERV_DSD Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 20,538
OVC_SERV_DSD Sum of Age/Sex disaggregates 2017 6,537
PMTCT_ART_DSD Already on ART at beginning of current pregnancy 2017 1,213
PMTCT_ART_DSD New on ART 2017 1,855
PMTCT_ART_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 105,368
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth 2017 2,931
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2017 3
PMTCT_EID_DSD Sum of Infant Age disaggregates 2017 2,934
PMTCT_STAT_DSD By: Known positives at entry 2017 1,052
PMTCT_STAT_DSD By: Number of new positives identified 2017 3,287
PMTCT_STAT_DSD Number of new ANC and L&D clients 2017 105,371
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 105,368
PMTCT_STAT_DSD Required only for DREAMS Countries - Denominator: 20-24 2017 1,846
PMTCT_STAT_DSD Required only for DREAMS Countries - Denominator: 25-49 2017 4,000
PMTCT_STAT_DSD Required only for DREAMS Countries - Denominator: <15 2017 62
PMTCT_STAT_DSD Required only for DREAMS Countries - Denominator: <15-19 2017 246
PMTCT_STAT_DSD Sum of Positives Status disaggregates 2017 4,339
TB_ART_DSD Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 671
TB_ART_DSD Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 42
TB_ART_DSD Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 346
TB_ART_DSD Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 37
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 3,325
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 1,100
TB_SCREENDX_DSD Screen Result: Screened Positive for TB 2017 7,786
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Female 2017 27,546
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Male 2017 13,089
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Female 2017 2,150
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Male 2017 2,065
TB_SCREENDX_DSD The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 44,849
TB_SCREENDX_DSD [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 797
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 67
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 496
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 402
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,057
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 143
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,072
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 136
TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 3,418
TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period 2017 3,406
TX_CURR_DSD Age/Sex: 10-14 Female 2017 22
TX_CURR_DSD Age/Sex: 10-14 Male 2017 21
TX_CURR_DSD Age/Sex: 15-19 Female 2017 20
TX_CURR_DSD Age/Sex: 15-19 Male 2017 11
TX_CURR_DSD Age/Sex: 20-24 Female 2017 82
TX_CURR_DSD Age/Sex: 20-24 Male 2017 20
TX_CURR_DSD Age/Sex: 25-49 Female 2017 697
TX_CURR_DSD Age/Sex: 25-49 Male 2017 302
TX_CURR_DSD Age/Sex: 50+ Female 2017 133
TX_CURR_DSD Age/Sex: 50+ Male 2017 102
TX_CURR_DSD Age/Sex: <1 2017 4
TX_CURR_DSD Age/Sex: <1-9 2017 100
TX_CURR_DSD Aggregated Age/Sex: 15+ Female 2017 27,579
TX_CURR_DSD Aggregated Age/Sex: 15+ Male 2017 13,045
TX_CURR_DSD Aggregated Age/Sex: <15 Female 2017 2,151
TX_CURR_DSD Aggregated Age/Sex: <15 Male 2017 2,077
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2017 44,851
TX_CURR_DSD Sum of age/sex disaggregates 2017 31
TX_CURR_DSD Sum of Aggregated Age/Sex 15+ 2017 40,624
TX_CURR_DSD Sum of Aggregated Age/Sex <15 2017 4,228
TX_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2017 44,852
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Female 2017 6,936
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Male 2017 3,399
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Female 2017 572
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Male 2017 546
TX_NEW_DSD By Age/Sex: 1-9 2017 23
TX_NEW_DSD By Age/Sex: 10-14 Female 2017 6
TX_NEW_DSD By Age/Sex: 10-14 Male 2017 6
TX_NEW_DSD By Age/Sex: 15-19 Female 2017 5
TX_NEW_DSD By Age/Sex: 15-19 Male 2017 2
TX_NEW_DSD By Age/Sex: 20-24 Female 2017 20
TX_NEW_DSD By Age/Sex: 20-24 Male 2017 6
TX_NEW_DSD By Age/Sex: 25-49 Female 2017 180
TX_NEW_DSD By Age/Sex: 25-49 Male 2017 78
TX_NEW_DSD By Age/Sex: 50+ Female 2017 33
TX_NEW_DSD By Age/Sex: 50+ Male 2017 28
TX_NEW_DSD By Age/Sex: <1 2017 1
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 11,474
TX_NEW_DSD Sum of Age/Sex disaggregates 2017 364
TX_NEW_DSD Sum of Aggregated Age/Sex disaggregates 2017 11,453
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Female 2017 31,009
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Male 2017 14,758
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Female 2017 2,395
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Male 2017 2,233
TX_PVLS_DSD Denominator: Indication: Routine 2017 45,313
TX_PVLS_DSD Denominator: Indication: Targeted 2017 5,082
TX_PVLS_DSD Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 50,517
TX_PVLS_DSD Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 50,837
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Female 2017 31,222
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Male 2017 14,858
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Female 2017 2,411
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Male 2017 2,249
TX_PVLS_DSD Numerator: Indication: Routine 2017 45,615
TX_PVLS_DSD Numerator: Indication: Targeted 2017 5,139
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5,034
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5,058
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,446
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,453
TX_RET_DSD Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 393
TX_RET_DSD Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 393
TX_RET_DSD Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 407
TX_RET_DSD Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 379
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 8,288
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 8,251
VMMC_CIRC_DSD By Age: 10-14 2017 6,791
VMMC_CIRC_DSD By Age: 15-19 2017 6,047
VMMC_CIRC_DSD By Age: 20-24 2017 1,834
VMMC_CIRC_DSD By Age: 25-29 2017 1,233
VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 2017 15,905
VMMC_CIRC_DSD Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 15,907
VMMC_CIRC_DSD Sum of age disaggregates (FY15-Current) 2017 15,905
VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 2017 14,672
Cross Cutting Budget Categories and Known Amounts Total: $283,000
Human Resources for Health $25,000
Food and Nutrition: Policy, Tools, and Service Delivery $10,000
Food and Nutrition: Commodities $25,000
Education $18,000
Key Populations: FSW $150,000
Monitoring and evaluation of SW programs
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: Gender Equality $5,000
Equity in HIV prevention, care, treatment and support
Condoms: Policy, Tools, and Services $50,000